Self-administered HPV screening promises greater patient comfort and higher detection rates, though solutions for large-scale rollout and follow-up are still needed.

A look back, a look ahead. In this webinar, Luke Greenwalt, MBA, of IQVIA and Jeff Casberg, RPh, M.S. of IPD Analytics will be discussing the MFN policy, the direct-to-consumer channel, the GLP-1 demand, the drug pipeline and more.

Colton Jones, M.D., of The University of Texas San Antonio, discusses aspirin for colorectal cancer prevention after presenting research comparing GLP-1s with aspirin at the 2026 ASCO Gastrointestinal Cancers Symposium earlier this month in San Francisco.

In 2024, U.S. health care spending rose to $5.3 trillion, driven by increased per capita use and demand for medical services as utilization rebounded following the COVID-19 pandemic.

Long-term Medicaid expansion was linked to substantial growth in PrEP prescribing, with earlier expansion states seeing far higher PrEP uptake relative to new HIV diagnoses, according to a recent study.

This segment summarizes practical guidance for patients, providers, and payers, emphasizing the need for comprehensive genomic testing and rapid access to targeted therapies.

This segment analyzes key limitations of current evidence—including the non-randomized design of PHAROS and challenges of cross-trial comparison—while underscoring the ongoing need for better strategies in non-V600E mutations.

This segment examines treatment considerations for patients with CNS involvement, stressing individualized decisions due to limited dedicated CNS data for encorafenib/binimetinib in lung cancer.